Shuttle Pharma appoints Adam Chambers to board

Q: What is Adam Chambers’ relationship to Shuttle Pharmaceuticals (SHPH)?

Adam Chambers is a director of the company and the principal of Bowery Consulting Group Inc., which is the lender under Shuttle Pharmaceuticals’ revolving loan agreement dated February 28, 2025.

Q: Are there any family relationships between Adam Chambers and SHPH executives or directors?

The company states that there are no family relationships between Adam Chambers and any of Shuttle Pharmaceuticals’ directors or executive officers.

Q: Did any arrangements or understandings lead to Adam Chambers’ appointment to the SHPH board?

The disclosure states that there were no arrangements or understandings by which Adam Chambers was appointed as a member of the Board of Directors.

Shuttle Pharmaceuticals Holdings, Inc. reported that its Board of Directors appointed Adam Chambers as a director effective September 8, 2025.

Accepted by SEC EDGAR 09/08/2025 - 05:00 PM EDT

Filing Impact

(Moderate)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Shuttle Pharmaceuticals Holdings, Inc. reported that its Board of Directors appointed Adam Chambers as a director effective September 8, 2025. Mr. Chambers is the principal of Bowery Consulting Group Inc., which is the lender under the Company’s revolving loan agreement dated February 28, 2025, and also a party to a consulting services agreement dated March 21, 2025. The Company states there are no family relationships between Mr. Chambers and any of its directors or executive officers, and, other than the loan and consulting agreements, he has no direct or indirect material interest in any transaction requiring disclosure under Item 404(a) of Regulation S-K. The filing also notes there were no arrangements or understandings by which he was appointed to the Board.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What board change did SHPH disclose in this 8-K filing?

The company disclosed that its Board of Directors appointed Adam Chambers as a director effective September 8, 2025.

What is Adam Chambers’ relationship to Shuttle Pharmaceuticals (SHPH)?

Adam Chambers is a director of the company and the principal of Bowery Consulting Group Inc., which is the lender under Shuttle Pharmaceuticals’ revolving loan agreement dated February 28, 2025.

What business agreements exist between SHPH and Bowery Consulting Group Inc.?

The filing states that Bowery Consulting Group Inc. is the lender under a revolving loan agreement dated February 28, 2025 and is also party to a consulting services agreement dated March 21, 2025 with Shuttle Pharmaceuticals.

Are there any family relationships between Adam Chambers and SHPH executives or directors?

The company states that there are no family relationships between Adam Chambers and any of Shuttle Pharmaceuticals’ directors or executive officers.

Did any arrangements or understandings lead to Adam Chambers’ appointment to the SHPH board?

The disclosure states that there were no arrangements or understandings by which Adam Chambers was appointed as a member of the Board of Directors.

Does Adam Chambers have other material interests in SHPH transactions requiring disclosure?

Other than the revolving loan agreement and the consulting services agreement with Bowery Consulting Group Inc., the filing states that Mr. Chambers does not have any direct or indirect material interest in transactions requiring disclosure under Item 404(a) of Regulation S-K.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 8, 2025

SHUTTLE PHARMACEUTICALS HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

Delaware

001-41488

82-5089826

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

401 Professional Drive, Suite 260

Gaithersburg, MD 20879

(Address of principal executive offices) (Zip Code)

(240) 430-4212

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock $0.00001 per share		SHPH		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 8, 2025, the Company’s Board of Directors appointed Adam Chambers as a director of the Company.

There are no family relationships between Mr. Chambers and any of the Company’s directors or executive officers. Mr. Chambers is the principal of Bowery Consulting Group Inc., which is the lender under the Company’s revolving loan agreement, dated February 28, 2025. In addition, the Company and Bowery Consulting Group Inc. also entered into a consulting services agreement dated March 21, 2025. Other than that, Mr. Chambers does not have any direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. There were no arrangements or understandings by which Mr. Chambers was appointed as a member of the Board of Directors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	SHUTTLE PHARMACEUTICALS HOLDINGS, INC.
Dated: September 8, 2025
	By:	/s/ Christopher Cooper
	Name:	Christopher Cooper
	Title:	Interim Chief Executive Officer

Source: View Original Filing on SEC EDGAR